The combination of FOLFOXIRI and molecular-targeted therapies, including bevacizumab, is a first-line treatment for mCRC (metastatic colorectal cancer) patients, i.e., more effective than chemotherapy alone.
✅ 𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: - https://www.marknteladvisors.c....om/research-library/
#colorectal_cancer_market #crc #colorectalcancer #antimetabolites #immunotherapy #tumor #marketresearch #healthcare #marknteladvisors
